Advertisement

Advertisement

HK:2367 Stock Latest News

Jill Wu Maintains Buy Rating, Slightly Lowers DCF-Based Target to HK$38.42 While Highlighting Diversified Growth and Injectables Upside

RatingsJill Wu Maintains Buy Rating, Slightly Lowers DCF-Based Target to HK$38.42 While Highlighting Diversified Growth and Injectables Upside

Giant Biogene’s Interim Profit Drops Amid Rising Expenses

PremiumCompany Announcements

Giant Biogene’s Interim Profit Drops Amid Rising Expenses

9d ago

Giant Biogene Wins China Approval for First Recombinant Type III Collagen Neck Filler

PremiumCompany Announcements

Giant Biogene Wins China Approval for First Recombinant Type III Collagen Neck Filler

2M ago

Giant Biogene Shareholders Back All AGM Resolutions, Approve Final and Special Dividends

PremiumCompany Announcements

Giant Biogene Shareholders Back All AGM Resolutions, Approve Final and Special Dividends

3M ago

Giant Biogene Declares Final 2025 Cash Dividend and Sets HKD Payout Terms

PremiumCompany Announcements

Giant Biogene Declares Final 2025 Cash Dividend and Sets HKD Payout Terms

3M ago

Giant Biogene Updates Details of 2025 Special Dividend Payout

PremiumCompany AnnouncementsGiant Biogene Updates Details of 2025 Special Dividend Payout

3M ago

Giant Biogene Moves to Replace EY with KPMG as External Auditor

Company Announcements

Giant Biogene Moves to Replace EY with KPMG as External Auditor

3M ago

Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor

Company Announcements

Giant Biogene Sets 2026 AGM to Refresh Board Mandates and Appoint New Auditor

4M ago

Giant Biogene Moves to Replace EY With KPMG as Auditor

PremiumCompany Announcements

Giant Biogene Moves to Replace EY With KPMG as Auditor

4M ago

Giant Biogene Reshapes Corporate Secretariat With New Joint Company Secretary

PremiumCompany Announcements

Giant Biogene Reshapes Corporate Secretariat With New Joint Company Secretary

5M ago

Giant Biogene: Buy Rating on Recovering Growth, High-Value Injectables, and Valuation Support from Buybacks and Channel Expansion

PremiumRatings

Giant Biogene: Buy Rating on Recovering Growth, High-Value Injectables, and Valuation Support from Buybacks and Channel Expansion

5M ago

Giant Biogene Posts Flat Revenue but Lower Profit and Maintains Robust Dividends for 2025

PremiumCompany Announcements

Giant Biogene Posts Flat Revenue but Lower Profit and Maintains Robust Dividends for 2025

5M ago

Giant Biogene Proposes Final Dividend for 2025 Financial Year

PremiumCompany AnnouncementsGiant Biogene Proposes Final Dividend for 2025 Financial Year

5M ago

Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position

Company Announcements

Giant Biogene Announces Special 2025 Dividend, Signaling Confidence in Cash Position

5M ago

Giant Biogene Sets March Board Meeting to Approve 2025 Results

Company Announcements

Giant Biogene Sets March Board Meeting to Approve 2025 Results

6M ago

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

PremiumCompany Announcements

Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant

7M ago

Giant Biogene Announces Share Repurchase Plan to Enhance Value

PremiumCompany Announcements

Giant Biogene Announces Share Repurchase Plan to Enhance Value

9M ago

Giant Biogene’s Controlling Shareholder Increases Stake to 54.66%

PremiumCompany Announcements

Giant Biogene’s Controlling Shareholder Increases Stake to 54.66%

10M ago

Giant Biogene Gains Approval for Innovative Collagen Product

PremiumCompany Announcements

Giant Biogene Gains Approval for Innovative Collagen Product

10M ago

Giant Biogene’s Controlling Shareholder Increases Stake

PremiumCompany AnnouncementsGiant Biogene’s Controlling Shareholder Increases Stake

10M ago

Giant Biogene’s Controlling Shareholder Increases Stake

Company Announcements

Giant Biogene’s Controlling Shareholder Increases Stake

10M ago

Giant Biogene’s Controlling Shareholder Boosts Stake, Signaling Confidence in Future Growth

Company Announcements

Giant Biogene’s Controlling Shareholder Boosts Stake, Signaling Confidence in Future Growth

11M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >